- Home
- LYEL vs RVPHW Comparison
LYEL vs RVPHW Comparison
Compare LYEL & RVPHW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYEL
- RVPHW
- Stock Information
- Founded
- LYEL 2018
- RVPHW 2018
- Country
- LYEL United States
- RVPHW United States
- Employees
- LYEL N/A
- RVPHW 14
- Industry
- LYEL Biotechnology: Pharmaceutical Preparations
- RVPHW Biotechnology: Pharmaceutical Preparations
- Sector
- LYEL Health Care
- RVPHW Health Care
- Exchange
- LYEL Nasdaq
- RVPHW Nasdaq
- Market Cap
- LYEL 207.7M
- RVPHW N/A
- IPO Year
- LYEL 2021
- RVPHW N/A
- Fundamental
- Price
- LYEL $9.84
- RVPHW $0.04
- Analyst Decision
- LYEL Sell
- RVPHW
- Analyst Count
- LYEL 2
- RVPHW 0
- Target Price
- LYEL $15.00
- RVPHW N/A
- AVG Volume (30 Days)
- LYEL 148.8K
- RVPHW 22.4K
- Earning Date
- LYEL 08-06-2025
- RVPHW 03-14-2025
- Dividend Yield
- LYEL N/A
- RVPHW N/A
- EPS Growth
- LYEL N/A
- RVPHW N/A
- EPS
- LYEL N/A
- RVPHW N/A
- Revenue
- LYEL $65,000.00
- RVPHW N/A
- Revenue This Year
- LYEL N/A
- RVPHW N/A
- Revenue Next Year
- LYEL N/A
- RVPHW N/A
- P/E Ratio
- LYEL N/A
- RVPHW N/A
- Revenue Growth
- LYEL N/A
- RVPHW N/A
- 52 Week Low
- LYEL $7.65
- RVPHW $0.13
- 52 Week High
- LYEL $38.40
- RVPHW $0.15
- Technical
- Relative Strength Index (RSI)
- LYEL 52.64
- RVPHW N/A
- Support Level
- LYEL $9.11
- RVPHW N/A
- Resistance Level
- LYEL $10.41
- RVPHW N/A
- Average True Range (ATR)
- LYEL 0.61
- RVPHW 0.00
- MACD
- LYEL 0.04
- RVPHW 0.00
- Stochastic Oscillator
- LYEL 70.77
- RVPHW 0.00
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About RVPHW Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.